Read previous post:
Analyst Douglas Loe says the visibility on future revenue growth drivers for cangene is still limited, especially in light of recent declines in the company's flagship product WinRho and hepatitis B treatment HepaGAM B.
Cangene revenue will remain lumpy, says Byron Capital’s Loe

Byron Capital analyst Douglas Loe says investors should not regard the numbers Cangene (TSX:CNJ) posted this week as the new...

Close